$1.87
1.63% today
Nasdaq, Feb 05, 04:16 pm CET
ISIN
US34960Q1094
Symbol
FBIO
Sector
Industry

Fortress Biotech, Inc. Stock price

$1.84
-0.42 18.58% 1M
+0.04 2.22% 6M
-0.19 9.14% YTD
+0.12 6.98% 1Y
-26.81 93.58% 3Y
-32.96 94.71% 5Y
-34.16 94.89% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
+0.02 0.82%
ISIN
US34960Q1094
Symbol
FBIO
Sector
Industry

Key metrics

Market capitalization $50.79m
Enterprise Value $29.57m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.47
P/S ratio (TTM) P/S ratio 0.81
P/B ratio (TTM) P/B ratio 2.40
Revenue growth (TTM) Revenue growth -22.81%
Revenue (TTM) Revenue $62.50m
EBIT (operating result TTM) EBIT $-103.46m
Free Cash Flow (TTM) Free Cash Flow $-153.25m
Cash position $58.85m
EPS (TTM) EPS $-3.27
P/E forward negative
P/S forward 0.86
EV/Sales forward 0.50
Short interest 11.50%
Show more

Is Fortress Biotech, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Fortress Biotech, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Fortress Biotech, Inc. forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a Fortress Biotech, Inc. forecast:

Buy
100%

Financial data from Fortress Biotech, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
63 63
23% 23%
100%
- Direct Costs 26 26
15% 15%
41%
37 37
27% 27%
59%
- Selling and Administrative Expenses 72 72
20% 20%
115%
- Research and Development Expense 61 61
52% 52%
98%
-96 -96
42% 42%
-154%
- Depreciation and Amortization 7.37 7.37
7% 7%
12%
EBIT (Operating Income) EBIT -103 -103
41% 41%
-166%
Net Profit -49 -49
38% 38%
-78%

In millions USD.

Don't miss a Thing! We will send you all news about Fortress Biotech, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Fortress Biotech, Inc. Stock News

Neutral
GlobeNewsWire
9 days ago
Study is the first randomized, controlled trial examining a vaccine's effectiveness in controlling CMV in recipients of HSCT from vaccinated donors
Neutral
GlobeNewsWire
13 days ago
Conference call and webcast scheduled to take place on Wednesday, February 5, 2025, at 4:30 p.m. E.T. Conference call and webcast scheduled to take place on Wednesday, February 5, 2025, at 4:30 p.m. E.T.
Neutral
GlobeNewsWire
about one month ago
Priority review granted for CUTX-101 with PDUFA target action date set for June 30, 2025 Cyprium is eligible to receive royalties and up to $129 million in aggregate development and sales milestones Cyprium also retains ownership over any Priority Review Voucher that may be issued at NDA approval MIAMI, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its...
More Fortress Biotech, Inc. News

Company Profile

Fortress Biotech, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel pharmaceutical and biotechnology products. It operates through the following segments: Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development. The company was founded on June 28, 2006 and is headquartered in New York, NY.

Head office United States
CEO Lindsay Rosenwald
Employees 186
Founded 2006
Website www.fortressbiotech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today